Nuvectis Pharma, Inc. (NVCT) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Nuvectis Pharma, Inc.

NVCT

NASDAQ

Unprofitable

Unprofitable

245M

Biotechnology

Next Earning date - 06 May 2025

245M

Biotechnology

Next Earning date - 06 May 2025

10.49USD

-0.47 ( -4.29%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

96

Volume Buzz

86%

Earning Acce

No

Dist 52w H.

11%

Quote Panel

Updated April 27, 2025

1W 25.78 % 1M 0.29 % 3M 64.42 % 1Y 64.42 %

Key Metrics

Market Cap
245.38M
Shares Outstanding
23.39M
Share in Float
12.11M
Dividende
0

Earning Date
06 May 2025
Price Target
10.49
Average Volume
125432
Beta
-0.12

Range
4.44-11.8
Industry
Biotechnology
Website
https://www.nuvectis.com
Sector
Healthcare

Fundamentals

Relative Strength

NVCT

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$23M

NaN%

2025-Revenue

$1.01

-172%

2025-EPS

$14M

315%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.27
vs -0.32

Q2.23

N/A

-0.38
vs -0.28

Q3.23

N/A

-0.37
vs -0.42

Q4.23

N/A

-0.41
vs -0.48

Q1.24

N/A

-0.25
vs -0.27

Q2.24

N/A

-0.26
vs -0.38

Q3.24

N/A

-0.24
vs -0.37

Q4.24

N/A

-0.36
vs -0.41

Q1.25

N/A

-0.25
vs -0.25

Q2.25

N/A

-0.25
vs -0.26

Sales Growth

YoY

Current

Estimates

Q3.22

NA

NA vs NA

Q4.22

+3625%

149K vs 4K

Q1.23

NA

4.1M vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

-2852%

-4101000.00 vs 149K

Q1.24

-100%

NA vs 4.1M

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Q4.24

+100%

NA vs -4101000

Return on Equity

QoQ

Q1.23

-33%

-0.33
vs -0.46

Q2.23

-28%

-0.28
vs -0.33

Q3.23

-35%

-0.35
vs -0.28

Q4.23

-54%

-0.54
vs -0.35

Q1.24

-30%

-0.30
vs -0.54

Q2.24

-35%

-0.35
vs -0.30

Q3.24

-38%

-0.38
vs -0.35

Q4.24

-64%

-0.64
vs -0.38

Institutionnal Ownership

QoQ

Q1.23

13

13
vs 11

18%

Q2.23

37

37
vs 13

185%

Q3.23

33

33
vs 37

-11%

Q4.23

36

36
vs 33

9%

Q1.24

40

40
vs 36

11%

Q2.24

39

39
vs 40

-2%

Q3.24

31

31
vs 39

-21%

Q4.24

31

31
vs 31

NA

Earnings Growth

Latest News

NVCT

globenewswire.com

8 hours ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

NVCT

businesswire.com

8 hours ago

Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

NVCT

globenewswire.com

8 hours ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

NVCT

globenewswire.com

9 hours ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

NVCT

businesswire.com

10 hours ago

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

NVCT

seekingalpha.com

14 hours ago

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback